Welcome to our dedicated page for ACOR news (Ticker: ACOR), a resource for investors and traders seeking the latest updates and insights on ACOR stock.
Acorda Therapeutics reports company developments tied to neurological therapies, product commercialization, and operating results. Recurring updates cover INBRIJA revenue and commercialization, AMPYRA sales, FAMPYRA rights and international arrangements, and the company’s ARCUS inhaled delivery technology.
Acorda news also includes quarterly and year-end financial-result announcements, webcast notices, material agreements, capital-structure disclosures, governance matters, and clinical or regulatory disclosures connected to its Parkinson’s disease and multiple sclerosis therapy portfolio.
Flow Sciences (ACOR) named Michael Gesser as chief financial officer effective April 8, 2026. Gesser, a Flow Sciences board member since 2021, will retain his board seat while overseeing finance, accounting, tax, treasury, FP&A and investor relations. The company highlights his 30+ years of life sciences financial leadership and ties to the RTP expansion opened in 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.